China Pharma Holdings, Inc. — Q1 2014 Form 10-Q
Business and period: The company manufactures and markets pharmaceutical and biochemical products primarily in China through its subsidiary Helpson. This unaudited report covers the three months ended March 31, 2014; comparative results are for Q1 2013. Amounts are in U.S. dollars.
Financial performance and position
| Metric | Q1 2014 / March 31, 2014 | Comparable period / December 31, 2013 |
|---|---|---|
| Revenue | $7.11 million | $8.25 million in Q1 2013; down 14% |
| Gross profit (margin) | $2.66 million (37%) | Loss of $1.57 million (negative 19%) |
| Operating loss | $2.34 million | $3.00 million in Q1 2013 |
| Net loss; loss per share | $2.39 million; $0.05 | $2.81 million; $0.06 in Q1 2013 |
| Operating cash flow | $2.49 million | $1.11 million in Q1 2013 |
| Cash and cash equivalents | $5.29 million | $5.99 million at December 31, 2013 |
| Total assets; total liabilities | $154.34 million; $24.91 million | $157.61 million; $24.67 million at December 31, 2013 |
| Debt | $4.87 million short-term notes and $12.98 million construction loan | Construction loan facility fully drawn by May 7, 2014, according to management |
Investing activities used $3.75 million, mainly for construction and equipment for the GMP upgrade; financing activities provided $0.61 million. Cash declined by $0.70 million during the quarter. Current assets were $77.88 million and current liabilities $11.73 million, but a substantial portion of current assets is receivables and cash held in China.
Changes and operating drivers
- Revenue declined, partly reflecting the company’s tighter screening of customers and distributors to prioritize collections and limit credit sales. Anti-infection and respiratory sales rose 8% to $5.0 million; CNS/cerebral/cardiovascular sales fell 57% to $0.9 million, primarily following the discontinuation of Buflomedil; digestive-disease sales fell 64% to $0.3 million.
- Gross margin improved from negative 19% to 37%, reflecting no inventory-obsolescence charge in Q1 2014 versus $3.69 million in Q1 2013, lower raw-material costs, and higher selling prices for certain products.
- Bad-debt expense was $3.31 million, versus a $0.12 million benefit in Q1 2013. Net trade receivables were $42.34 million, with a $16.47 million allowance. Management reported $39.5 million of receivables past due; 21.8% of receivables were over 720 days old.
- R&D expense increased to $0.44 million from $0.17 million. The company reported no inventory-obsolescence expense in Q1 2014.
Outlook, risks and commitments
- Two older injectable-product lines were suspended on January 1, 2014 after missing the new GMP-upgrade deadline. The new facility’s main building was complete and its lines were being tested and commissioned. Management intended to apply for a new GMP certificate in June 2014 and expected issuance three to six months after application; these are expectations, not guarantees.
- Management said operating cash flow should cover working capital and anticipated capital expenditures for the next 12 months, but noted that changed circumstances could require additional financing or spending reductions. It also stated that the $5.29 million cash balance was considered indefinitely reinvested in Helpson and was not expected to be available to the parent or shareholders.
- CFDA review delays may extend formula approvals; approval typically takes two to five years and could take longer. The company had approximately $41.35 million in advances for formula purchases and was obligated to pay about $5.42 million over roughly four years as contractual milestones are completed.
- PRC currency conversion and remittance controls may restrict transfers to the parent. The company also faces pricing pressure, regulatory and operating risks in China, and customer/supplier concentration: one customer represented 16.6% of Q1 sales and one supplier 37.5% of raw-material purchases.
- The construction loan bears 7.205% interest, with principal installments beginning July 2015. The short-term credit line bears 6.6%, is collateralized, personally guaranteed by the CEO and board chair, and had no remaining availability. No off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Whether the new facility obtained GMP approval and restarted production as planned, and how the shutdown affected subsequent sales and capacity.
- Receivables aging, collectability, allowance adequacy, and the effect of customer payment delays on cash generation.
- Availability of cash held in China, upcoming construction-loan principal payments, and funding needs for facility completion and formula commitments.
- Progress and timing of CFDA approvals and whether the associated advances and contractual refunds are recoverable if approvals fail.
- Resolve disclosure inconsistencies: the financial statements report Q1 2014 income-tax expense of $19,347, while MD&A describes a tax benefit of approximately $0.2 million; MD&A also characterizes operating cash flow as decreasing even though the cash-flow statement shows an increase from $1.11 million to $2.49 million.